The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes-Reference-Cited by-同舟云学术

The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes

Published:2012-05 Issue:5 Volume:36 Page:525-536
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Platzbecker Uwe,Hofbauer Lorenz C.,Ehninger Gerhard,Hölig Kristina

Funder

Celgene Corporation

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference79 articles.

1. Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life;Balducci;Cancer,2006

2. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology;Alessandrino;Haematologica,2002

3. Current therapeutic approaches for patients with myelodysplastic syndromes;Greenberg;Br J Haematol,2010

4. Quality of life (QoL) in myelodysplastic syndromes (MDS): an update of results from US & European patient forums [abstract];Heptinstall;Leuk Res,2007

5. Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies;Kelaidi;Haematologica,2010

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparación de un hemoglobinómetro portátil (Verio Q Red) con los resultados del laboratorio clínico en la práctica clínica habitual;Atención Primaria;2025-02

2. Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome;Blood Advances;2024-08-13

3. Contemporary Challenges in Polycythemia Vera Management From the Perspective of Patients and Physicians;Clinical Lymphoma Myeloma and Leukemia;2024-08

4. Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape;Current Oncology;2024-04-03

5. Structure‐Based Design of AG‐946, a Pyruvate Kinase Activator;ChemMedChem;2024-02-02